Changes in inflammation, oxidative stress, mitochondrial DNA content after rosiglitazone in HIV lipoatrophy

Journal of AIDS and Clinical Research

Volumn 3, Issue 8, 2012, Pages

  Tungsiripat, Marisa ^a   El Bejjani, Dalia ^a   Rizk, Nesrine ^b   Hu, Bo ^a   Ross, Allison C ^b   Walker, Ulrich A ^c,d   Lebrecht, Dirk ^c   Milne, Ginger ^e   Storer, Norma ^b   McComsey, Grace A ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY OF FREIBURG   (Germany)

^d Department of Rheumatology ^*  (Switzerland)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AntiRetroviral therapy; Fat loss; Lipoatrophy; Mitochondrial DNA; Oxidative stress; Rosiglitazone

Indexed keywords

EID: 84879806385     PISSN: None     EISSN: 21556113     Source Type: Journal    
DOI: 10.4172/2155-6113.1000174     Document Type: Article

References (31)

1. Dukers NH, Stolte IG, Albrecht N, Coutinho RA, de Wit JB (2001) The impact of experiencing lipodystrophy on the sexual behaviour and well-being among HIV-infected homosexual men. Aids 15: 812-813.
2. McComsey GA, Paulsen DM, Lonergan JT, Hessenthaler SM, Hoppel CL, et al. (2005) Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. Aids 19: 15-23.
3. Milinkovic A, Martinez E, López S, de Lazzari E, Miró O, et al. (2007) The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir Ther 12: 407-415.
4. Viengchareun S, Caron M, Auclair M, Kim MJ, Frachon P, et al. (2007) Mitochondrial toxicity of indinavir, stavudine and zidovudine involves multiple cellular targets in white and brown adipocytes. Antivir Ther 12: 919-929.
5. Carr A, Workman C, Carey D, Rogers G, Martin A, et al. (2004) No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 363: 429-438.
6. Cavalcanti RB, Raboud J, Shen S, Kain KC, Cheung A, et al. (2007) A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy. J Infect Dis 195: 1754-1761.
7. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, et al. (2004) Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med 140: 786-794.
8. Mulligan K, Yang Y, Wininger DA, Koletar SL, Parker RA, et al. (2007) Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. Aids 21: 47-57.
9. Slama L, Lanoy E, Valantin MA, Bastard JP, Chermak A, et al. (2008) Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). Antivir Ther 13: 67-76.
10. Sutinen J, Häkkinen AM, Westerbacka J, Seppälä-Lindroos A, Vehkavaara S, et al. (2003) Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study. Antivir Ther 8: 199-207.
11. van Wijk JP, de Koning EJ, Cabezas MC, op't Roodt J, Joven J, et al. (2005) Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. Ann Intern Med 143: 337-346.
12. Mallon PW, Sedwell R, Rogers G, Nolan D, Unemori P, et al. (2008) Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction. J Infect Dis 198: 1794-1803.
13. Tungsiripat M, Bejjani DE, Rizk N, O'riordan MA, Ross AC, et al. (2010) Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens. AIDS 24: 1291-1218.
14. McComsey GA, Morrow JD (2003) Lipid oxidative markers are significantly increased in lipoatrophy but not in sustained asymptomatic hyperlactatemia. J Acquir Immune Defic Syndr 34: 45-49.
15. Morrow JD, Roberts LJ (1996) The isoprostanes. Current knowledge and directions for future research. Biochem Pharmacol 51: 1-9.
16. Samaras K, Gan SK, Peake PW, Carr A, Campbell LV (2009) Proinflammatory markers, insulin sensitivity, and cardiometabolic risk factors in treated HIV infection. Obesity (Silver Spring) 17: 53-59.
17. Setzer B, Schlesier M, Walker UA (2005) Effects of of didanosine-related depletion of mtDNA in human T lymphocytes. J Infect Dis 191: 848-855.
18. Carr A, Workman C, Smith DE, Hoy J, Hudson J, et al. (2002) Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. Jama 288: 207-215.
19. Martin A, Smith DE, Carr A, Ringland C, Amin J, et al. (2004) Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. Aids 18: 1029-1036.
20. Moyle GJ, Sabin CA, Cartledge J, Johnson M, Wilkins E, et al. (2006) A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. Aids 20: 2043-2050.
21. Tungsiripat M, El-Bejjani D, Rizk N, Dogra V, O'Riordan MA, et al. (2011) Carotid Intima Media Thickness, Inflammatory Markers, and Endothelial Activation Markers in HIV Patients with Lipoatrophy Increased at 48 Weeks Regardless of Use of Rosiglitazone or Placebo. AIDS Res Hum Retroviruses 27: 295-302.
22. Ross AC, Armentrout R, O'Riordan MA, Storer N, Rizk N, et al. (2008) Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy. J Acquir Immune Defic Syndr 49: 499-506.
23. El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, et al. (2008) Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med 149: 289-299.
24. Torriani FJ, Komarow L, Parker RA, Cotter BR, Currier JS, et al. (2008) Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 52: 569-576.
25. Cherry CL, Gahan ME, McArthur JC, Lewin SR, Hoy JF, et al. (2002) Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. J Acquir Immune Defic Syndr 30: 271-277.
26. McComsey G, Southwell H, Gripshover B, Salata R, Valdez H (2003) Effect of antioxidants on glucose metabolism and plasma lipids in HIV-infected subjects with lipoatrophy. J Acquir Immune Defic Syndr 33: 605-607.
27. Nolan D, Mallal S (2003) Thymidine analogue-sparing highly active antiretroviral therapy (HAART). J HIV Ther 8: 2-6.
28. McComsey GA, Libutti DE, O'Riordan M, Shelton JM, Storer N, et al. (2008) Mitochondrial RNA and DNA alterations in HIV lipoatrophy are linked to antiretroviral therapy and not to HIV infection. Antivir Ther 13: 715-722.
29. Ward WF, Qi W, Van Remmen H, Zackert WE, Roberts LJ, 2nd, et al. (2005) Effects of age and caloric restriction on lipid peroxidation: measurement of oxidative stress by F2-isoprostane levels. J Gerontol A Biol Sci Med Sci 60: 847-851.
30. Hulgan T, Morrow J, D'Aquila RT, Raffanti S, Morgan M, et al. (2003) Oxidant stress is increased during treatment of human immunodeficiency virus infection. Clin Infect Dis 37: 1711-1717.
31. Gupta SK, Shen C, Moe SM, Kamendulis LM, Goldman M, et al. (2012) Worsening Endothelial Function with Efavirenz Compared with Protease Inhibitors: a 12-Month Prospective Study. PloS ONE 7: e45719